Advertisement
Advertisement
U.S. markets close in 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

RVL Pharmaceuticals plc (O1P.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
1.3700+0.0100 (+0.74%)
As of 09:15AM CET. Market open.
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

    BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a panel presentation and host 1x1 investor meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference in Miami, FL, as follows: Date:Thursday, December 8, 2022 Time: 9:00am ET 1x1 investor meetings can be requested via co

  • Zacks Small Cap Research

    RVLP: Can’t Take My Eyes Off You

    By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT We are initiating coverage of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share. RVL’s lead and only marketed asset is Upneeq®, a product developed to treat acquired blepharoptosis, or low-lying eyelids. Following approval for Upneeq in July 2020, RVL embarked on a structured commercialization effort

  • GlobeNewswire

    RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update

    -- Third quarter 2022 UPNEEQ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022 -- -- Anticipates fourth quarter 2022 UPNEEQ net product sales to grow approximately 20% - 40% over the third quarter 2022, representing sales of approximately $12 - $14 million

Advertisement
Advertisement